MALVERN, Pa., Dec. 16, 2013 /PRNewswire/ — Accretive transaction furthers Endo’s transformation into leading specialty healthcare company Builds on Endo’s leadership in pain management through addition of ZECUITY® (sumatriptan iontophoretic transdermal system), the first and only FDA approved patch to treat migraine Proven Endo branded pharmaceuticals commercial team to execute ZECUITY launch, expected in first half 2014 Endo […]
— European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union — FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 13, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the single tablet HIV-1 regimen Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable […]
Data Monitoring Committee recommends continuation of Phase II/III EPOCH study in mild to moderate disease patients Merck also plans to initiate dosing in Phase III study of prodromal disease patients WHITEHOUSE STATION, N.J. December 10, 2013 — (BUSINESS WIRE) –Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the […]
Data Presented at American Society of Hematology (ASH) Meeting Demonstrates Therapeutic Levels of Gene Modification in Sangamo’s In Vivo Protein Replacement Platform RICHMOND, Calif., Dec. 10, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new pre-clinical data demonstrating therapeutic levels of gene modification in non-human primates (NHPs) from its In Vivo Protein Replacement Platform. Based […]
MALVERN, Pa., Dec. 10, 2013 /PRNewswire/ — Endo Health Solutions (NASDAQ: ENDP) today announced that Arthur J. Higgins has been appointed to its Board of Directors, effective immediately. Endo also announced that Joseph C. Scodari, 60, will retire as a director, effective December 31, 2013. Recognized for his strategic capabilities, Mr. Higgins has over 30 […]
Novel Genome-Editing Approach Offers a Potential Cure for Both Diseases RICHMOND, Calif., Dec. 9, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of preclinical data from its ZFP Therapeutic program for the treatment and potential cure of both sickle cell disease (SCD) and beta-thalassemia. The data demonstrate that Sangamo’s approach, using its proprietary and highly specific […]
– Interim Analyses from Phase 3 Pediatric Studies Suggest Prolonged Half-Life of Investigational Long-Lasting Therapies in Children Under Age 12 – CAMBRIDGE, Mass. & STOCKHOLM–(December 9, 2013)–Today Biogen Idec (NASDAQ:BIIB) and Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:SOBI) announced new results from Phase 3 studies of their investigational long-lasting recombinant factor IX and VIII Fc fusion protein candidates for […]
RetroArc Extends the AMS™ Continence Sling Portfolio to Provide More Options for Women With SUI MINNEAPOLIS, Dec. 9, 2013 /PRNewswire/ — American Medical Systems® Inc. (AMS), an Endo Health Solutions Inc. (Nasdaq: ENDP) subsidiary and leading provider of devices and therapies for male and female pelvic health, today announced FDA 510(k) Clearance of its RetroArc™ Retropubic Sling System for treatment of female stress […]
NEW YORK– December 9, 2013 — (BUSINESS WIRE) –Forest Laboratories, Inc. (NYSE:FRX) today announced appointments to its executive leadership team. The appointments are part of Forest’s announced plans to flatten and broaden the organization as part of Project Rejuvenate. “Today we are announcing an important step to rejuvenate our company by creating the first Forest Executive Team […]
57 Percent Overall Response Rate and Median Duration of Response of 12.5 Months in Heavily Pre-Treated Patients Data Presented at American Society of Hematology Annual Meeting NEW ORLEANS, Dec 08, 2013 (BUSINESS WIRE) –Gilead Sciences, Inc. (Nasdaq: GILD) today announced results of a Phase 2 study (Study 101-09) evaluating idelalisib, an investigational oral inhibitor of PI3K […]